MedTrace Logo

AZD6140 Oral Contraceptive Interaction Study

NCT00685906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-12-02

No results posted yet for this study

Summary

The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones.

Conditions

  • Healthy

Interventions

DRUG

AZD6140

90 mg tablet taken by mouth 2 times a day for 21 days per cycle

DRUG

Levonorgestrel and Ethinyl Estradiol (Nordette®)

1 tablet taken by mouth once a day for 28 days per cycle

Sponsors & Collaborators

Principal Investigators

  • Kathleen Butler, MD · AstraZeneca

  • Audrey, Martinez, MD · SeaView Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685906 on ClinicalTrials.gov